

Conflict of Interest (COI) Checklist for the Rocky Mountain/ACP Annual Meeting Committee

Nov 2015 – Nov 2016

Dr. Michel Sauve

The 2015 Program for the Rocky Mountain/ACP Internal Medicine Conference will be reviewed and approved for study hour credits under Section 1 (Accredited Group Learning Activities) of the Framework of Continuing Professional Development (CPD) Options of the RCPSC Maintenance of Certification Program. In order to meet these requirements, the following conditions must be met.

Ethical Standards: Disclosure

All events and programs approved under Section 1 and Section 3 must adhere to the following conflicts of interest standards:

1. All faculty and planning committee members participating in accredited CPD events must provide a written description of their relationships with members of the pharmaceutical industry and other commercial industry as defined by the CMA Guidelines, *Physicians and the Pharmaceutical Industry (2007)* <http://policybase.cma.ca/dbtw-wpd/Policypdf/PD08-01.pdf>.
2. All faculty and planning committee members must disclose all relationships (not just those directly related to the topic or content being discussed at the event) over the previous two years.
3. The written description of the relationships of faculty and planning committee members must be provided to participants. This must either be part of the written conference material or described in the second slide at the time of the presentation.
4. There should be disclosure of any “off-label” use of pharmaceutical agents or medical devices.

A disclosure of a potential conflict of interest (COI) does not mean there has been an actual COI in regards to one’s dealings with the meeting, nor if there was an actual COI that the terms of our accreditation have been violated. It simply is a statement of disclosure (which is the requirement of accreditation) and that participants will then be able to take that information into consideration when assessing the validity and integrity of the materials presented in relation to that statement.

Therefore, I am asking each member of the Annual Meeting Committee to complete this form. As the Chair of the Committee, I will be making a formal, public statement of disclosure for myself (for which there are no COIs) to the participants of the meeting in my Opening Remarks. Also, since I have perceived no commercial bias in any of my dealings with the members of this Committee, either individually or as a group in our development and presentation of the meeting, I will be making a general statement as to whether there are, or there are no potential COI for Committee members, without identifying who or what these may be. I will then point the participants who have an interest in these matters to the RM website where the details of all of our COI statements may be accessed.

All Faculty that are presenting at the meeting have been asked to include a disclosure statement on the second slide of their presentations. All the presentations and these disclosure statements will eventually appear on the RM website.

Please circle the appropriate response for each of the following questions and provide details where your answer is affirmative. Please use a separate sheet of paper if required.

- 1) Have you had any direct dealings with the Pharmaceutical or other commercial industry in the medical field over the last 2 years in any of the following areas:

Research/clinical studies directly funded by Pharma or commercial industry? Yes No
(If Yes, please provide details)

Seminars or promotional meetings sponsored by Pharma or commercial industry? Yes No
(If Yes, please provide details)

CME where speaker is sponsored by Pharma

Attended a conference or meeting where all or part of the travel and accommodation costs were paid for by Pharma or commercial industry? Yes No
(If Yes, please provide details)

Provided expert advice to Pharma or commercial industry, in any form? Yes No
(If Yes, please provide details)

Ad boards for Abbvie for Biologics for inflammatory bowel disease

- 2) Do you own shares (apart from mutual funds) in Pharma or any commercial industry with a product or competing product in the medical field under discussion in this Program? Yes No
(If Yes, what is their current value?)



Signature

October 27, 2016
Date